Penserra Capital Management LLC bought a new stake in Alkermes plc (NASDAQ:ALKS - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 23,010 shares of the company's stock, valued at approximately $759,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of ALKS. RTW Investments LP grew its stake in Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock valued at $217,363,000 after purchasing an additional 903,802 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Alkermes by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock worth $157,568,000 after purchasing an additional 57,697 shares during the last quarter. American Century Companies Inc. raised its holdings in Alkermes by 6.5% in the 4th quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock valued at $99,242,000 after acquiring an additional 209,740 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Alkermes by 4.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock valued at $86,842,000 after acquiring an additional 128,701 shares in the last quarter. Finally, Avoro Capital Advisors LLC acquired a new position in shares of Alkermes during the 4th quarter worth $70,462,000. Institutional investors and hedge funds own 95.21% of the company's stock.
Insiders Place Their Bets
In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of the firm's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total transaction of $103,654.06. Following the sale, the senior vice president owned 86,208 shares in the company, valued at $2,680,206.72. This trade represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.40% of the stock is owned by insiders.
Alkermes Stock Performance
NASDAQ ALKS traded down $0.18 on Friday, hitting $30.28. 1,483,309 shares of the stock traded hands, compared to its average volume of 1,735,394. The business's fifty day moving average is $30.15 and its two-hundred day moving average is $30.90. Alkermes plc has a 12 month low of $23.12 and a 12 month high of $36.45. The firm has a market capitalization of $4.99 billion, a price-to-earnings ratio of 14.49, a PEG ratio of 1.88 and a beta of 0.44.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a return on equity of 27.52% and a net margin of 23.30%. The company had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. During the same period in the previous year, the business earned $0.43 earnings per share. Alkermes's revenue was down 12.6% on a year-over-year basis. Analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on ALKS shares. Cantor Fitzgerald upgraded Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. UBS Group raised Alkermes from a "neutral" rating to a "buy" rating and upped their price target for the stock from $33.00 to $42.00 in a research note on Tuesday, June 17th. HC Wainwright reaffirmed a "neutral" rating on shares of Alkermes in a research note on Friday, May 2nd. Needham & Company LLC started coverage on Alkermes in a research note on Wednesday, May 28th. They issued a "buy" rating and a $45.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $40.00.
Check Out Our Latest Report on Alkermes
About Alkermes
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Read More
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
